ALSO NOTED: Spin-off may signal new era for Big Pharma R&D; Shire plots $394M Massachusetts plant;

> The Wall Street Journal notes the "dis-integration" of the traditional Big Pharma model following yesterday's announcement that AstraZeneca is spinning off its Swedish R&D facility for gastrointestinal therapies. Report

> U.K. drug maker Shire plans to build a new, $394 million manufacturing plant in Massachusetts and to add 680 jobs to its operations in the state over the next eight years. Report

> More U.S. adults are taking prescription drugs than ever, fueling $12 billion in additional spending during 2006. Report

> India's Cadila Healthcare got tentative FDA approval for its copycat version of carvedilol. Report

> Cadence Pharmaceuticals plans a private placement of 9.2 million shares of common stock in hopes of raising almost $50 million. Report

> Thailand will decide next week whether to negate compulsory licenses on four cancer drugs. Report

> Publicis, an advertising company whose pharma clients didn't get new drugs approved in 2007, missed its revenue-growth targets for the year. Report

> TorreyPines Therapeutics is taking a lashing from some of the analysts for its decision to cut staff as it restructures the company and focuses on its lead development programs. Report

> The House Committee on Energy and Commerce says it won't investigate a controversial FDA advisory committee vote on Dendreon's Provenge. Report

> Amgen CEO Kevin Sharer dropped by The Wall Street Journal to tout the company's chances in developing denosumab (D-mab) into a badly needed blockbuster. Report

And Finally... Soon, a urine test may be able to diagnose coronary artery disease. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.